Rayos

(Prednisone)

ApprovedSmall molecule

Prednisone is a steroid medication that reduces inflammation and suppresses the immune system, used to treat conditions like allergies, asthma, arthritis, and certain autoimmune diseases.[2] Rayos is currently approved and in use across 253 indications[4].[1]

Rayos is one of 2047 small molecule programs targeting Lymphoma. It is currently in Approved.

253

Indications

1,228

Total Trials

Active Trials

2,046

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

LymphomaCompleted

Prostate AdenocarcinomaRecruiting

Diffuse Large B-Cell LymphomaTerminated

Lupus NephritisCompleted

AsthmaNot yet recruiting

T-Cell Acute Lymphoblastic LeukemiaActive, not recruiting

EfficacyCompleted

LenalidomideCompleted

Efficacy and SafetyNot yet recruiting

Abiraterone AcetateCompleted

LymphomaPhase 3

Completed

Prostate AdenocarcinomaApproved

Recruiting

Diffuse Large B-Cell LymphomaPhase 3

Terminated

Lupus NephritisPhase 3

Completed

AsthmaApproved

Not yet recruiting

T-Cell Acute Lymphoblastic LeukemiaPhase 3

Active, not recruiting

EfficacyPhase 3

Completed

LenalidomidePhase 2

Completed

Efficacy and SafetyApproved

Not yet recruiting

Abiraterone AcetatePhase 3

Completed

Showing 10 of 252 indications

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Rayos

Cabenuva

1 3

Norvir

AbbVie

Preclinical

1 4

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 5

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 6

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—7

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—8

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

1 10

Antibody-Drug Conjugate

MMBrace Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Metastatic Prostate Cancer

NCT03821792

Phase 1Recruiting

Acute Lymphoblastic Leukemia

NCT04872790

Recruiting

Pregnancy

NCT04918524

Q1 2027

Phase 2Recruiting

Lymphoma

NCT05958719

Phase 1Not yet recruiting

Lymphoma

NCT07278856

Q2 2027

Recruiting

Asthma

NCT00576069

Clinical

Trials by Indication[1]

Lymphoma40 trials

A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00451178·101 enrolled

R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00809341·27 enrolled

Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma

Completed·UUniversity of Nebraska·Phase 1/2·NCT02561273·54 enrolled

Show 37 more trials

Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 3·NCT02767674·258 enrolled

GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma

Unknown status·FFrench Innovative Leukemia Organisation·Phase 2·NCT00896519·30 enrolled

SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma

Completed·SSWOG Cancer Research Network·Phase 3·NCT00004031·397 enrolled

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Completed·UUniversity of Nebraska·Phase 2·NCT00004197

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06630091·30 enrolled

Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma

Completed·SSt. Jude Children's Research Hospital·N/A·NCT00187122·42 enrolled

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00003204·515 enrolled

BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas

Enrolling by invitation·NN.N. Petrov National Medical Research Center of Oncology·Phase 3·NCT07258680·114 enrolled

Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00012207·12 enrolled

R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma

Unknown status·WWenqi Jiang·Phase 3·NCT02428751·216 enrolled

Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma

Completed·FFondazione Michelangelo·Phase 3·NCT01251107·331 enrolled

Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05958719·37 enrolled

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

Terminated· Bayer logo

Bayer·Phase 3·NCT02626455·551 enrolled

Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00032019·78 enrolled

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

Not yet recruiting·—·Phase 1·NCT07278856·20 enrolled

Treatment of Aggressive Localized Lymphoma

Terminated·FFrench Innovative Leukemia Organisation·Phase 3·NCT00841945·334 enrolled

Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.

Unknown status·PPETHEMA Foundation·Phase 2·NCT05049473·100 enrolled

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

Terminated·—·Phase 2·NCT01746173·5 enrolled

Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00088881·62 enrolled

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00003595·120 enrolled

Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma

Completed·CChristine Mauz-Körholz·Phase 3·NCT00433459·2,134 enrolled

Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT00352027·81 enrolled

Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma

Completed·LLymphoma Study Association·Phase 2·NCT00136565·60 enrolled

Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma

Suspended·HHenan Cancer Hospital·Phase 2·NCT04668365·59 enrolled

Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma

Completed·UUnknown Sponsor·Phase 3·NCT00052936·1,506 enrolled

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Completed· Roche logo

Roche·Phase 1·NCT03467373·111 enrolled

Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda

Terminated·FFred Hutchinson Cancer Center·Phase 1·NCT03864419·18 enrolled

Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma

Unknown status·FFondazione Italiana Linfomi - ETS·Phase 2·NCT01009970·50 enrolled

S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00770224·87 enrolled

Combination Chemotherapy in Treating Children With Lymphoma

Completed·CChildren's Oncology Group·Phase 2·NCT00002590·221 enrolled

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

Completed·UUniversity of Nebraska·Phase 2·NCT01336933·34 enrolled

Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00002524·46 enrolled

Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients

Unknown status·NNanfang Hospital, Southern Medical University·Phase 3·NCT03023358·174 enrolled

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

Active, not recruiting·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT04479267·8 enrolled

Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma

Completed·UUnknown Sponsor·Phase 2·NCT00290667·586 enrolled

Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma

Unknown status· Amgen logo

Amgen·Phase 2·NCT00005959

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01445535·15 enrolled

Prostate Cancer27 trials

Docetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy

Completed·WWake Forest University Health Sciences·Phase 2·NCT00416533·47 enrolled

Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Active, not recruiting·MMamta Parikh·Phase 2·NCT02807805·37 enrolled

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Completed·EExelixis·Phase 3·NCT01605227·1,028 enrolled

Show 24 more trials

Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer

Terminated·—·Phase 1/2·NCT00996502·4 enrolled

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

Recruiting·SSWOG Cancer Research Network·Phase 3·NCT06470243·528 enrolled

Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone

Withdrawn·SStanford University·Phase 1·NCT04296578

A Study of Olaratumab (IMC-3G3) in Prostate Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01204710·123 enrolled

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

Terminated·UUniversity of Southern California·Phase 2·NCT01469338·9 enrolled

Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy

Completed·—·Phase 2·NCT02903368·118 enrolled

Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients

Completed· Pfizer logo

Pfizer·Phase 4·NCT01995513·509 enrolled

Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT00887198·1,088 enrolled

Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer

Completed·RRahul Aggarwal·Phase 1·NCT01594918·25 enrolled

Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

Terminated·UUniversity of Washington·Phase 2·NCT03649841·10 enrolled

Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer

Completed·SSanta Chiara Hospital·Phase 2·NCT02453009·246 enrolled

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Recruiting· Astellas logo

Astellas·Phase 1·NCT04729114·174 enrolled

A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01715285·1,209 enrolled

Satraplatin and Prednisone to Treat Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00634647·24 enrolled

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT04907227·81 enrolled

Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer

Terminated·SSandy Srinivas·Phase 1·NCT01155791·2 enrolled

Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC)

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT00811031

A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT04100018·1,030 enrolled

A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

Completed·UUniversity of Washington·Phase 2·NCT02849990·22 enrolled

An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00544440·57 enrolled

Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer

Completed·—·Phase 2·NCT01393730·40 enrolled

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

Recruiting·—·Phase 2·NCT04734730·70 enrolled

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Terminated·UUniversity of California, Davis·Phase 2·NCT02844582·2 enrolled

A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00683475·138 enrolled

Acute Lymphoblastic Leukemia11 trials

Cemiplimab in AlloSCT/SOT Recipients With CSCC

Completed·—·Phase 1/2·NCT04339062·12 enrolled

S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·SSWOG Cancer Research Network·Phase 2·NCT00109837·79 enrolled

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2/3·NCT03117751·790 enrolled

Show 8 more trials

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

Completed· Incyte logo

Incyte·Phase 2·NCT02723994·171 enrolled

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

Recruiting·OOHSU Knight Cancer Institute·Phase 1·NCT04872790·20 enrolled

Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone

Withdrawn·UUniversity of Utah·Phase 1·NCT02815059

Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients

Unknown status·TTongji Hospital·Phase 4·NCT02690922·40 enrolled

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia

Completed·UUniversity Hospital Schleswig-Holstein·Phase 3·NCT01117441·6,136 enrolled

Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia

Withdrawn·MMayo Clinic·Phase 2·NCT01670084

LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive

Completed·PPETHEMA Foundation·Phase 4·NCT00526305·100 enrolled

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Withdrawn·UUniversity of Washington·Phase 2·NCT02538926

Diffuse Large B-Cell Lymphoma11 trials

Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

Completed· Takeda logo

Takeda·Phase 2·NCT00931918·206 enrolled

Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Terminated· Pfizer logo

Pfizer·Phase 2·NCT01925612·87 enrolled

Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00121199·73 enrolled

Show 8 more trials

Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma

Unknown status·FFondazione Italiana Linfomi - ETS·Phase 3·NCT00499018·399 enrolled

A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)

Completed· Roche logo

Roche·Phase 2·NCT01414855·100 enrolled

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Active, not recruiting·MMayo Clinic·Phase 1·NCT04323956·50 enrolled

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02285062·570 enrolled

Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma

Withdrawn·FFox Chase Cancer Center·Phase 2·NCT01539174

A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

Terminated· Roche logo

Roche·Phase 3·NCT01287741·1,418 enrolled

Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00301821·107 enrolled

Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma

Unknown status·WWuhan University·Phase 3·NCT02449265·160 enrolled

Multiple Myeloma6 trials

Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.

Completed·PPETHEMA Foundation·Phase 1/2·NCT00388635·60 enrolled

Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years

Active, not recruiting·PPETHEMA Foundation·Phase 3·NCT03742297·462 enrolled

Bortezomib With Melphalan and Prednisone for Multiple Myeloma

Completed·—·Phase 2·NCT00734149·45 enrolled

Show 3 more trials

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Terminated·OOncotherapeutics·Phase 2·NCT02294357·45 enrolled

S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00040937·147 enrolled

Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma

Completed· Takeda logo

Takeda·Phase 1/2·NCT01335685·61 enrolled

80 more indications

Metastatic Prostate Cancer6 trials

Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Completed·NNCIC Clinical Trials Group·Phase 2·NCT00258388·82 enrolled

Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer

Completed·OOHSU Knight Cancer Institute·Phase 2·NCT00182741·19 enrolled

Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03821792·60 enrolled

Show 3 more trials

Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00527124·57 enrolled

XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer

Completed· Sanofi logo

Sanofi·Phase 3·NCT00417079·755 enrolled

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Completed·DDavid Oh·Phase 2·NCT03007732·23 enrolled

Kidney Transplant5 trials

A Pharmacokinetic Study of CellCept (Mycophenolate Mofetil) Versus Mycophenolate Sodium in Kidney Transplant Patients

Completed· Roche logo

Roche·Phase 4·NCT01033864·23 enrolled

A Study Comparing Outcomes of Kidney Transplants in Patients on Steroids Versus Those Who Discontinue Steroids

Unknown status·—··NCT00273559·60 enrolled

Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00311311·72 enrolled

Show 2 more trials

Study of Tacrolimus Immunosuppressive Therapy After Kidney Transplantation

Completed· Astellas logo

Astellas·Phase 4·NCT00717379·50 enrolled

Steroid Withdrawal in Pediatric Kidney Transplant Recipients

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00023244·274 enrolled

Leukemia5 trials

Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT00002766·170 enrolled

Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia

Terminated·EEastern Cooperative Oncology Group·Phase 2·NCT00003910·59 enrolled

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00133991·23 enrolled

Show 2 more trials

Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia

Completed·CChildren's Oncology Group·Phase 2·NCT00003783·36 enrolled

Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma

Completed·CChildren's Oncology Group·Phase 2·NCT00057811·97 enrolled

Abiraterone Acetate4 trials

Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01946165·69 enrolled

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01517802·32 enrolled

Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations

Withdrawn·QQian Qin·Phase 2·NCT06392841

Show 1 more trial

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

Recruiting·EEmory University·Phase 3·NCT06650579·72 enrolled

Heart Failure3 trials

Effect of Short-term Prednisone Therapy on C-reactive Protein in Patients With Acute Heart Failure

Completed·HHeart Initiative·N/A·NCT05916586·101 enrolled

Prednisone for Heart Failure Patients With Hyperuricemia

Completed·HHebei Medical University·Phase 2/3·NCT02129764·205 enrolled

Efficacy and Safety of corticoSTEROids Added to Standard Therapy in Patients With Acute Heart Failure (STERO-AHF)

Unknown status·AAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia·Phase 2/3·NCT05809011·120 enrolled

Asthma3 trials

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

Recruiting·GGelb, Arthur F., M.D.··NCT00576069·60 enrolled

Inflammatory, Functional and Image Composite Measure to Define Asthma Control

Unknown status·FFederal University of São Paulo·Phase 4·NCT00597064·70 enrolled

Asthma Exacerbation Study

Withdrawn·UUniversity of Pittsburgh·N/A·NCT00853411

Chemotherapy2 trials

Reduced Chemotherapy in Low Risk DLBCL

Unknown status·RRuijin Hospital·Phase 4·NCT02752815·290 enrolled

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Terminated·EExelixis·Phase 2·NCT01995058·54 enrolled

Pregnancy2 trials

Prednisone Plus IVIg vs. Prednisone for ITP During Pregnancy

Recruiting·PPeking University People's Hospital·Phase 2·NCT06577909·100 enrolled

The Clinical Features and Pregnancy Outcomes of CTD Patients

Recruiting·QQilu Hospital of Shandong University··NCT04918524·126 enrolled

Hodgkin's Disease2 trials

Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease

Terminated·SStanford University·Phase 2·NCT00225173·45 enrolled

Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

Completed·CChildren's Oncology Group·Phase 3·NCT00005578·219 enrolled

Allogeneic Hematopoietic Cell Transplant2 trials

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT02356159·34 enrolled

Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03663933·71 enrolled

Treatment2 trials

Biomarker Guided Treatment in DLBCL

Unknown status·RRuijin Hospital·Phase 2·NCT04025593·128 enrolled

LAL-BR/2001: Study Treatment to Low Risk ALL

Completed·PPETHEMA Foundation·Phase 4·NCT00526175·150 enrolled

Arthritis1 trial

Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis

Recruiting·TTom Appleton·Phase 2·NCT06037811·30 enrolled

Acute Graft Versus Host Disease1 trial

Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)

Completed·MMesoblast, Ltd.·Phase 2·NCT00136903·32 enrolled

IgG4 Related Disease1 trial

Belimumab Treatment for IgG4-related Disease

Unknown status·PPeking Union Medical College Hospital·Phase 4·NCT04660565·60 enrolled

Hemangioma1 trial

Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Infantile Hemangioma

Completed·UUniversity of Sao Paulo·Phase 2·NCT01072045·50 enrolled

ART1 trial

Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants

Completed·CCorcept Therapeutics·Phase 1·NCT04672512·115 enrolled

Atopic Dermatitis1 trial

A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis

Terminated· Eli Lilly logo

Eli Lilly·Phase 1·NCT06119529·18 enrolled

Immune Thrombocytopenia1 trial

Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia

Completed·UUniversity Hospital, Essen·Phase 3·NCT02334813·26 enrolled

Stage III1 trial

Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL

Terminated·UUniversity of Miami·N/A·NCT00772668·3 enrolled

Thrombocytopenic Purpura1 trial

Initial Treatment of Patients With Immune Thrombocytopenic Purpura

Terminated·CCarelon Research·Phase 3·NCT00991939·8 enrolled

Transplantation1 trial

Study in Human iPSCs-derived RPE Cells Transplantation for Late-Stage AMD

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1/2·NCT07418177·9 enrolled

Advanced Cancer1 trial

A Study of LY3039478 in Participants With Advanced Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01695005·247 enrolled

HIV infection1 trial

Combination Chemotherapy in Treating Patients With Hodgkin's Disease and HIV Infection

Unknown status·CCentro di Riferimento Oncologico - Aviano·Phase 2·NCT00003262·30 enrolled

Long QT Syndrome1 trial

Novel Form of Acquired Long QT Syndrome

Unknown status·NNarrows Institute for Biomedical Research·Phase 4·NCT04169100·25 enrolled

Combination Therapy1 trial

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Terminated·EExelixis·Phase 1·NCT04726332·52 enrolled

Hematologic Cancer1 trial

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

Completed·UUniversity of California, San Francisco·Phase 1·NCT00304018·5 enrolled

Acquired Hemophilia1 trial

Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A

Terminated·GGeorgetown University·Phase 2/3·NCT00306670·2 enrolled

Corticosteroids1 trial

Treatment Efficacy of Systemic Corticosteroids in AECOPD Patients With Higher Blood Eosinophil Levels

Terminated·—·Phase 4·NCT05059873·11 enrolled

Sickle Cell Disease1 trial

Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00034528·2 enrolled

Fanconi Anemia1 trial

Gene Therapy for Fanconi Anemia

Terminated·FFred Hutchinson Cancer Center·Phase 1·NCT01331018·3 enrolled

Phase II1 trial

A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07034508·134 enrolled

Granuloma1 trial

A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis

Completed· Roche logo

Roche·Phase 4·NCT02115997·30 enrolled

Diabetes Mellitus1 trial

Effect of Short Course of Glucocorticoid in Patients With Diabetes Mellitus(DM) Type 2

Completed·CCook County Health·Phase 1·NCT03661684·10 enrolled

Sciatica1 trial

Effectiveness of Oral Prednisone in Improving Physical Functioning and Decreasing Pain in People With Sciatica

Completed·KKaiser Permanente·Phase 2·NCT00668434·269 enrolled

Pediatric1 trial

Pediatric GVHD Low Risk Steroid Taper Trial

Active, not recruiting·JJohn Levine·Phase 2·NCT05090384·50 enrolled

Pemphigus Vulgaris1 trial

Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone

Completed·TTehran University of Medical Sciences·Phase 2·NCT00626678·48 enrolled

Lung Transplantation1 trial

Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation

Completed·WWashington University School of Medicine·Phase 2·NCT03388008·27 enrolled

Tics1 trial

Study to Evaluate the Effect of Multiple Doses of BIIL 284 BS on the Pharmacokinetics of Prednisone in Healthy Male Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02268149·20 enrolled

Lupus Nephritis1 trial

A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients

Terminated· Astellas logo

Astellas·Phase 3·NCT01342016·84 enrolled

Tocilizumab1 trial

Tocilizumab Plus a Short Prednisone Taper for GCA

Completed·MMassachusetts General Hospital·Phase 4·NCT03726749·30 enrolled

Male Infertility1 trial

Male Infertility Related With Post Infection Inflammatory Syndrome

Completed·AAssistance Publique - Hôpitaux de Paris·N/A·NCT01407484·200 enrolled

Withdrawal1 trial

Effect of Rapid Steroid Withdrawal on Subclinical Markers of Rejection

Terminated· Astellas logo

Astellas·Phase 4·NCT00133172·85 enrolled

Necrosis1 trial

RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor

Completed·AAndres J. M. Ferreri·Phase 2·NCT03536039·28 enrolled

Focal Segmental Glomerulosclerosis1 trial

Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

Completed· Astellas logo

Astellas·Phase 2·NCT02921789·67 enrolled

Hepatitis C1 trial

Study the Relationship Between Obesity and Hepatitis C Replication

Withdrawn·UUniversity of California, San Diego·Phase 2·NCT01157975

Myelofibrosis1 trial

Pomalidomide for Myelofibrosis Patients

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00946270·70 enrolled

Androgen Deprivation Therapy1 trial

Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

Terminated·—·Phase 3·NCT03777982·12 enrolled

Churg-Strauss syndrome1 trial

Rituxan in Churg Strauss Syndrome With Renal Involvement

Terminated·FFernando Fervenza·Phase 2·NCT00424749·4 enrolled

Muscular Dystrophy1 trial

Weekly Steroids in Muscular Dystrophy

Completed·NNorthwestern University·Phase 2·NCT04054375·20 enrolled

B-cell Lymphoid Malignancies1 trial

Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies

Active, not recruiting·MMedical College of Wisconsin·Phase 1·NCT05270057·11 enrolled

Adult Acute Lymphoblastic Leukemia1 trial

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

Terminated·UUniversity of California, San Diego·Phase 2·NCT02043587·31 enrolled

Glucocorticoids1 trial

Glucocorticoids in Patients With IgG4-RD

Unknown status·PPeking Union Medical College Hospital·Phase 2/3·NCT01758393·40 enrolled

Side Effects1 trial

Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects

Unknown status·HHoly Name Medical Center, Inc.·Phase 4·NCT03424733·50 enrolled

End Stage Renal Disease (ESRD)1 trial

A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT06814132·24 enrolled

Bone Marrow Transplantation1 trial

Withdrawn·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02702960

Pneumonia1 trial

Efficacy Studies of Corticosteroid Therapy in Community-Acquired Pneumonia

Completed·MMedical Center Alkmaar·Phase 3·NCT00170196·216 enrolled

Opioid Use Disorder1 trial

PROUD Study - Preventing Opioid Use Disorders

Terminated·EEmory University·Phase 4·NCT04766996·57 enrolled

Bell's palsy1 trial

Intratympanic Steroid for Bell's Palsy

Completed·UUniversity of Missouri-Columbia·Phase 2/3·NCT03508440·10 enrolled

Proteinuria1 trial

The Research of Standard Diagnosis and Treatment for HSPN With Mild Proteinuria in Children

Unknown status·NNanjing Children's Hospital·Phase 2·NCT02532790·100 enrolled

Viral Pneumonia1 trial

Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection

Terminated·HHospices Civils de Lyon·Phase 2·NCT04344288·11 enrolled

COVID-191 trial

Corticosteroids for COVID-19

Withdrawn·UUniversity of Alberta·Phase 3·NCT04795583

Allograft1 trial

Belatacept Therapy for the Failing Renal Allograft

Completed·AAndrew B Adams·Phase 3·NCT01921218·13 enrolled

Radius Fracture1 trial

Prednisone for CRPS in Distal Radius Fracture

Recruiting·UUniversity of British Columbia·N/A·NCT06453447·40 enrolled

Drug1 trial

Cortisone or Drug Eluting Stents (DES) as Compared to Bare Metal Stents (BMS) to EliminAte Restenosis

Completed·UUniversita di Verona·Phase 2/3·NCT00369356·375 enrolled

Colitis1 trial

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Active, not recruiting·MMassachusetts General Hospital·Phase 2·NCT04305145·42 enrolled

Richter's Transformation1 trial

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

Recruiting·WWeill Medical College of Cornell University·Phase 2·NCT04679012·20 enrolled

HIV-associated nephropathy1 trial

A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000819·54 enrolled

Chronic Graft Versus Host Disease1 trial

Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease

Completed·—·Phase 2·NCT00815919·22 enrolled

Anaplastic Large Cell Lymphoma1 trial

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00365274·6 enrolled

Newly Diagnosed1 trial

Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

Active, not recruiting·CChildren's Oncology Group·Phase 2·NCT00107198·188 enrolled

Uveitis1 trial

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

Completed· Sanofi logo

Sanofi·Phase 2·NCT01900431·58 enrolled

Moderate to Severe Crohn's Disease1 trial

Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease

Completed· AbbVie logo

AbbVie·Phase 3·NCT01235689·252 enrolled

Myelodysplastic Syndrome1 trial

Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome

Unknown status·OOffice of Rare Diseases (ORD)·Phase 2·NCT00466843·54 enrolled

Follicular Lymphoma1 trial

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)

Completed· Roche logo

Roche·Phase 3·NCT01889069·159 enrolled

Dexamethasone1 trial

Short-course High-dose Prednisone and Dexamethasone in Children With ITP

Recruiting·FFujian Medical University Union Hospital·Phase 4·NCT05522465·608 enrolled

Autoimmune Disease1 trial

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

Active, not recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT00716066·53 enrolled

Inflammation1 trial

Effect of Steroids on Thrombosis (Blood Clot Formation) and Inflammation in Patients Undergoing Hip Surgery

Completed·HHospital for Special Surgery, New York·N/A·NCT01782859·40 enrolled

Real-world Study1 trial

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Recruiting·RRuijin Hospital··NCT05899621·332 enrolled

Cancer of the Prostate1 trial

Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate

Withdrawn·JJohn P. Fruehauf·Phase 2·NCT00598858

Multiple Sclerosis1 trial

Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00014755·35 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

DELTASONE

NDA NDA009986

Jan 1, 1982

METICORTEN

NDA NDA009766

Jan 1, 1982

PARACORT

NDA NDA010962

Jan 1, 1982

PREDNISONE

NDA NDA017109

Jul 26, 2012

RAYOS

NDA NDA202020

Sources

References

[1]
ClinicalTrials.gov — 1228 trial records for Prednisone. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Rayos drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Prednisone compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Prednisone. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA202020). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Rayos. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Roxane Laboratories company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Glucocorticoid Receptor Agonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: RRoxane Laboratories

Patent Landscape[6]

Patent Cliff

Aug 3, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

9504699Aug 3, 2027

8168218Jan 7, 2028